Cognitive Decline in Post-treatment Lyme Disease Syndrome

Pegah Touradji, John Aucott, Ting Yang, Alison W. Rebman, Kathleen Bechtold Kortte

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Patient-reported cognitive complaints are common in those with post-treatment Lyme disease syndrome (PTLDS). Objective evidence of cognitive impairment in this population is variable in part due to methodological variability in existing studies. In this study, we sought to use a systematic approach to characterizing PTLDS based on the most current consensus diagnosis. We further examined PTLDS-related cognitive decline, operationalized as a significant decline in cognitive test performance relative to premorbid cognitive ability. METHOD: We enrolled a case series of 124 patients with confirmed PTLDS defined by Infectious Diseases Society of America-proposed case definition. Cognitive functioning was evaluated using standardized neuropsychological measures. RESULTS: The majority (92%) of participants endorsed some level of cognitive difficulty, yet 50% of the sample showed no statistically or clinically significant cognitive decline, 26% of the sample evidenced significant cognitive decline on measures of memory and variably on measures of processing speed, and 24% of the sample were excluded from analyses due to suboptimal test engagement. CONCLUSIONS: The current findings are consistent with the literature showing that the most robust neurocognitive deficit associated with PTLDS is in verbal memory and with variable decline in processing speed. Compared to population normative comparison standards, PTLDS-related cognitive decline remains mild. Thus, further research is needed to better understand factors related to the magnitude of subjective cognitive complaints as well as objective evidence of mild cognitive decline.

Original languageEnglish (US)
Pages (from-to)455-465
Number of pages11
JournalArchives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
Volume34
Issue number4
DOIs
StatePublished - Jun 1 2019

Fingerprint

Lyme Disease
Therapeutics
Aptitude
Cognitive Dysfunction
Population
Research

Keywords

  • Infections diseases
  • Mild cognitive impairment
  • non-HIV

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

@article{f59ebd86b3814217b702a24bbe59b9c3,
title = "Cognitive Decline in Post-treatment Lyme Disease Syndrome",
abstract = "OBJECTIVE: Patient-reported cognitive complaints are common in those with post-treatment Lyme disease syndrome (PTLDS). Objective evidence of cognitive impairment in this population is variable in part due to methodological variability in existing studies. In this study, we sought to use a systematic approach to characterizing PTLDS based on the most current consensus diagnosis. We further examined PTLDS-related cognitive decline, operationalized as a significant decline in cognitive test performance relative to premorbid cognitive ability. METHOD: We enrolled a case series of 124 patients with confirmed PTLDS defined by Infectious Diseases Society of America-proposed case definition. Cognitive functioning was evaluated using standardized neuropsychological measures. RESULTS: The majority (92{\%}) of participants endorsed some level of cognitive difficulty, yet 50{\%} of the sample showed no statistically or clinically significant cognitive decline, 26{\%} of the sample evidenced significant cognitive decline on measures of memory and variably on measures of processing speed, and 24{\%} of the sample were excluded from analyses due to suboptimal test engagement. CONCLUSIONS: The current findings are consistent with the literature showing that the most robust neurocognitive deficit associated with PTLDS is in verbal memory and with variable decline in processing speed. Compared to population normative comparison standards, PTLDS-related cognitive decline remains mild. Thus, further research is needed to better understand factors related to the magnitude of subjective cognitive complaints as well as objective evidence of mild cognitive decline.",
keywords = "Infections diseases, Mild cognitive impairment, non-HIV",
author = "Pegah Touradji and John Aucott and Ting Yang and Rebman, {Alison W.} and Kortte, {Kathleen Bechtold}",
year = "2019",
month = "6",
day = "1",
doi = "10.1093/arclin/acy051",
language = "English (US)",
volume = "34",
pages = "455--465",
journal = "Archives of Clinical Neuropsychology",
issn = "0887-6177",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Cognitive Decline in Post-treatment Lyme Disease Syndrome

AU - Touradji, Pegah

AU - Aucott, John

AU - Yang, Ting

AU - Rebman, Alison W.

AU - Kortte, Kathleen Bechtold

PY - 2019/6/1

Y1 - 2019/6/1

N2 - OBJECTIVE: Patient-reported cognitive complaints are common in those with post-treatment Lyme disease syndrome (PTLDS). Objective evidence of cognitive impairment in this population is variable in part due to methodological variability in existing studies. In this study, we sought to use a systematic approach to characterizing PTLDS based on the most current consensus diagnosis. We further examined PTLDS-related cognitive decline, operationalized as a significant decline in cognitive test performance relative to premorbid cognitive ability. METHOD: We enrolled a case series of 124 patients with confirmed PTLDS defined by Infectious Diseases Society of America-proposed case definition. Cognitive functioning was evaluated using standardized neuropsychological measures. RESULTS: The majority (92%) of participants endorsed some level of cognitive difficulty, yet 50% of the sample showed no statistically or clinically significant cognitive decline, 26% of the sample evidenced significant cognitive decline on measures of memory and variably on measures of processing speed, and 24% of the sample were excluded from analyses due to suboptimal test engagement. CONCLUSIONS: The current findings are consistent with the literature showing that the most robust neurocognitive deficit associated with PTLDS is in verbal memory and with variable decline in processing speed. Compared to population normative comparison standards, PTLDS-related cognitive decline remains mild. Thus, further research is needed to better understand factors related to the magnitude of subjective cognitive complaints as well as objective evidence of mild cognitive decline.

AB - OBJECTIVE: Patient-reported cognitive complaints are common in those with post-treatment Lyme disease syndrome (PTLDS). Objective evidence of cognitive impairment in this population is variable in part due to methodological variability in existing studies. In this study, we sought to use a systematic approach to characterizing PTLDS based on the most current consensus diagnosis. We further examined PTLDS-related cognitive decline, operationalized as a significant decline in cognitive test performance relative to premorbid cognitive ability. METHOD: We enrolled a case series of 124 patients with confirmed PTLDS defined by Infectious Diseases Society of America-proposed case definition. Cognitive functioning was evaluated using standardized neuropsychological measures. RESULTS: The majority (92%) of participants endorsed some level of cognitive difficulty, yet 50% of the sample showed no statistically or clinically significant cognitive decline, 26% of the sample evidenced significant cognitive decline on measures of memory and variably on measures of processing speed, and 24% of the sample were excluded from analyses due to suboptimal test engagement. CONCLUSIONS: The current findings are consistent with the literature showing that the most robust neurocognitive deficit associated with PTLDS is in verbal memory and with variable decline in processing speed. Compared to population normative comparison standards, PTLDS-related cognitive decline remains mild. Thus, further research is needed to better understand factors related to the magnitude of subjective cognitive complaints as well as objective evidence of mild cognitive decline.

KW - Infections diseases

KW - Mild cognitive impairment

KW - non-HIV

UR - http://www.scopus.com/inward/record.url?scp=85058920156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058920156&partnerID=8YFLogxK

U2 - 10.1093/arclin/acy051

DO - 10.1093/arclin/acy051

M3 - Article

C2 - 29945190

AN - SCOPUS:85058920156

VL - 34

SP - 455

EP - 465

JO - Archives of Clinical Neuropsychology

JF - Archives of Clinical Neuropsychology

SN - 0887-6177

IS - 4

ER -